No Data
No Data
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
Express News | HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Is Maintained at Outperform by BMO Capital
Korro Bio Is Maintained at Outperform by BMO Capital
Express News | BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target
No Data